{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:43:29Z","timestamp":1767926609972,"version":"3.49.0"},"reference-count":56,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Asthma"],"published-print":{"date-parts":[[2025,5,4]]},"DOI":"10.1080\/02770903.2024.2448736","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T16:02:11Z","timestamp":1737475331000},"page":"850-860","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Analysis of the economically justifiable price of mepolizumab in adults with asthma in Colombia"],"prefix":"10.1080","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2404-6612","authenticated-orcid":false,"given":"Jefferson Antonio","family":"Buendia","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, University of Antioquia","place":["Medell\u00edn, Colombia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Guerrero-Patino","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children\u2019s Hospital of Medellin","place":["Medell\u00edn, Colombia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Antonio","family":"Buendia Sanchez","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, University of Antioquia","place":["Medell\u00edn, Colombia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30925-9"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2015.36.3908"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-12-17"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12232"},{"key":"e_1_3_2_6_1","first-page":"106","article-title":"Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA Approved for Maintenance Treatment of Patients with Severe Asthma","volume":"9","author":"Fala L.","year":"2016","unstructured":"Fala L. Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA Approved for Maintenance Treatment of Patients with Severe Asthma. Am Health Drug Benefits. 2016;9(Spec Feature):106\u2013110.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_2_7_1","unstructured":"Agency EM. Nucala. 2015. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nucala."},{"key":"e_1_3_2_8_1","volume-title":"Drugs and lactation database (LactMed(R))","year":"2006","unstructured":"Mepolizumab. In Drugs and lactation database (LactMed(R)). Bethesda (MD): National Institute of Child Health and Human Development; 2006."},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.49781"},{"key":"e_1_3_2_10_1","unstructured":"Prevention G.S.f.A.M.a. Global initiative for asthma; 2023. Available from: https:\/\/ginasthma.org\/."},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2015.1025793"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/heapol\/czw096"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7197.1551"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.27269"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.06.014"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.06.012"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1148"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30125-X"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14221"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2022.2011217"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2021.1984527"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2023.2267129"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2021.1980586"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2021.1945445"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00745-2022"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010834.pub4"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.30789\/rcneumologia.v31.n2.2019.405"},{"key":"e_1_3_2_30_1","unstructured":"Excellence. N.I.f.H.a.C. Single Technology Appraisal. Reslizumab for treating eosinophilic asthma inadequately controlled on inhaled corticosteroids. 2017. Available from: www.nice.org.uk\/guidance\/ta479\/history."},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.30789\/rcneumologia.v27.n2.2015.25"},{"key":"e_1_3_2_32_1","first-page":"31","article-title":"Perfil cl\u00ednico y costos directos de la atenci\u00f3n de asma en una red de instituciones de salud en Bogot\u00e1","volume":"31","author":"Rosselli D","year":"2020","unstructured":"Rosselli D, et\u00a0al. Perfil cl\u00ednico y costos directos de la atenci\u00f3n de asma en una red de instituciones de salud en Bogot\u00e1. Revista Colombiana de Neumolog\u00eda. 2020;31:31.","journal-title":"Revista Colombiana de Neumolog\u00eda"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.11.021"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.1351"},{"key":"e_1_3_2_35_1","unstructured":"Salud I.d.E.T.e. Manual metodol\u00f3gico para la elaboraci\u00f3n de evaluaciones de efectividad seguridad y validez diagn\u00f3stica de tecnolog\u00edas en salud. 2014. Available from: https:\/\/www.minsalud.gov.co\/sites\/rid\/Lists\/BibliotecaDigital\/RIDE\/INEC\/IETS\/manual-metodologico-elaboracion-de-evaluaciones-de-efectividad.pdf."},{"key":"e_1_3_2_36_1","unstructured":"Estadisticas D.A.N. \u00cdndice de Precios al Consumidor - IPC. 2020. [cited 18 February 2020]. Available from: https:\/\/www.dane.gov.co\/index.php\/estadisticas-por-tema\/precios-y-costos\/indice-de-precios-al-consumidor-ipc."},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab118"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26920"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(23)00162-6"},{"key":"e_1_3_2_40_1","article-title":"Estimating cost-effectiveness thresholds under a managed healthcare system: experiences from Colombia","author":"Espinosa O","year":"2021","unstructured":"Espinosa O, et\u00a0al. Estimating cost-effectiveness thresholds under a managed healthcare system: experiences from Colombia. Health Policy Plan. 2021.","journal-title":"Health Policy Plan"},{"key":"e_1_3_2_41_1","unstructured":"Departamento Nacional and D.E. (DANE). Archivo Nacional de Datos. 2019. [cited 03 April 2020]; Available from: https:\/\/sitios.dane.gov.co\/anda-index\/."},{"key":"e_1_3_2_42_1","unstructured":"Garc\u00eda Calder\u00f3n CP BM. Eosin\u00f3filos en sangre y en esputo como predictores de severidad en crisis asm\u00e1tica. 2010. Available from: https:\/\/revistas.asoneumocito.org\/index.php\/rcneumologia\/article\/view\/679."},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1590\/s1020-49892005000300007"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2016.10.028"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2020.1837158"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2022.12.007"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2022.2896"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.23034"},{"key":"e_1_3_2_49_1","unstructured":"S K I S Y Y. Cost-effectiveness of mepolizumab versus omalizumab as an adjunct therapy in patients with uncontrolled allergic asthma. 2018. Available from: https:\/\/www.valueinhealthjournal.com\/article\/S1098-3015(18)31899-0\/fulltext."},{"key":"e_1_3_2_50_1","unstructured":"Cost-effectiveness analysis of dupilumab mepolizumab and benralizumab for severe eosinophilic asthma with blood eosinophil count \u2265300 cells\/\u00b5L in the Brazilian private healthcare perspective. 2022. Available from: https:\/\/www.ispor.org\/docs\/default-source\/euro2022\/poster\u2013-cost-effectiveness-eosinophilic-asthma-vfinalv2-pdf.pdf?sfvrsn=40f2c353_0."},{"issue":"6","key":"e_1_3_2_51_1","first-page":"187","article-title":"Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma","volume":"43","author":"Garcia-Mochon L","year":"2019","unstructured":"Garcia-Mochon L, et\u00a0al. Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma. Farm Hosp. 2019;43(6):187\u2013193.","journal-title":"Farm Hosp"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2022.2139718"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2023.2282668"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26033"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2022.11.002"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462320000033"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462321000416"}],"container-title":["Journal of Asthma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/02770903.2024.2448736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T14:54:48Z","timestamp":1745333688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/02770903.2024.2448736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,4]]}},"alternative-id":["10.1080\/02770903.2024.2448736"],"URL":"https:\/\/doi.org\/10.1080\/02770903.2024.2448736","relation":{},"ISSN":["0277-0903","1532-4303"],"issn-type":[{"value":"0277-0903","type":"print"},{"value":"1532-4303","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijas20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijas20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-11-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}